40 years of reform and opening up, 15 maps to understand China's pharmaceutical industry
This year marks the 40th anniversary of reform and opening up. Over the past 40 years, my country's pharmaceutical industry has made great achievements. The following are four aspects: global status, domestic growth, internationalization process, and capitalization process.
1. Global Status
(1) Scale: No. 2 in the world
1. Scale
China's pharmaceutical market has surpassed Japan to become the world's second largest pharmaceutical market. In 2015, China's pharmaceutical market accounted for 10.8% of the world's total.
40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry (Figure 1)
2. Enterprise: 2 pharmaceutical companies entered the world's top 500
On July 19, 2018, the "2018 Fortune Global 500 List" was officially released, and a total of 13 pharmaceutical companies around the world were on the list. Among them, two Chinese pharmaceutical companies, China Resources and China Pharmaceutical Group, entered the list, ranking 86th and 194th respectively. With a revenue of 82.184 billion US dollars, China Resources Co., Ltd. ranks first among pharmaceutical companies and ranks 86th in the overall list. This is also the first time that China Resources has once again ranked first in revenue among pharmaceutical companies after last year (of course, China Resources also includes the pharmaceutical industry. Business other than business), China National Pharmaceutical Group ranked 194th with a revenue of 51.844 billion U.S. dollars, an improvement of 5 places from 199 in 2017.
40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry (Figure 2)
China National Pharmaceutical Group has entered the list of the world's top 500 companies for six consecutive years since 2013, and its ranking has increased year by year
40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry (Figure 3)
3. Raw materials: No. 1 in the world in terms of output
40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry (Figure 4)
China has long been the country with the largest market share in the production of raw materials in the world.
(2) R&D
Since the release of the State Council Document No. 44 in 2015, China has launched a drug regulatory reform aimed at innovation and in line with international standards, and has achieved phased results, which has greatly improved the comprehensive competitiveness of China's pharmaceutical industry, especially its research and development capabilities.
1. The number of new drug research companies in China ranks third in the world
In 2016, China has become the largest pharmaceutical innovation base in Asia (Figure 5). According to the statistics of Pharmaprojects, as of January 2018, there are 4,134 pharmaceutical companies in the world that have developed new drugs (by country/region where the headquarters are located), among which, China The number of new drug research and development companies ranks third with Canada, accounting for 5% (Figure 6).
40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry (Figure 5)
40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry (Figure 6)
2. The number of clinical trials initiated in China ranks fourth in the world
40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry (Figure 7)
3. The number of biosimilar research and development in China ranks first in the world
In terms of research and development of small molecule drugs, there is still a big gap between China and developed countries, but the research and development of biological drugs started late in the world, and at this time, China's overall national strength has been greatly improved, unprecedented drug regulatory reforms have been launched, and a large number of returnees Factors such as scientists returning to China to join the ranks of new drug innovation have enabled China's biomedical research and development to develop rapidly. China is already the country with the largest number of biosimilar research and development.
40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry (Figure 8)
2. Domestic growth
1. Sales revenue scale
Over the past 40 years of reform and opening up, the sales revenue of China's pharmaceutical industry has increased from 7.28 billion yuan in 1978 to 2,982.6 billion yuan in 2017, an increase of more than 400 times.
40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry (Figure 9)
In addition, according to Mr. Yu Mingde, director of the expert committee and honorary chairman of the China Pharmaceutical Enterprise Management Association, from 1978 to 2017, the export value of the pharmaceutical industry increased from 280 million US dollars to 60.8 billion US dollars, an increase of 217 times, and the import value also increased from 0.4 billion to $55.88 billion, an increase of 1397 times.
2. Independent new drug research and development
Looking at the research and development of China's independent innovative drugs, it has gone through two important stages, one is 2002-2005 represented by the research and development of icotinib, apatinib and conbercept, and the other is since 2013 Especially since the State Council issued Document No. 44 in August 2015, the number of clinical applications for China's independent innovative drugs has increased significantly.
40 years of reform and opening up 15 charts to understand China's pharmaceutical industry (Figure 10)
3. Internationalization process
(1) go out
1. Chinese pharmaceutical companies rush to the US FDA to declare ANDA
According to incomplete statistics, the number of US ANDA approvals held by Chinese pharmaceutical companies has reached more than 430 (including acquisitions)
40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry (Figure 11)
2. Cross-border M&A
With the increasing scarcity of domestic pharmaceutical M&A targets and the steep rise in valuation, well-known domestic pharmaceutical companies represented by Fosun, Luye, Shanghai Pharmaceuticals and Humanwell have gone out to search for M&A targets on a global scale, and the results have been remarkable.
40 years of reform and opening up, 15 pictures to understand China's pharmaceutical industry (Figure 12)
(2) Please come in
Since August 2, 1980, when my country's first joint venture pharmaceutical company - China Otsuka Pharmaceutical Co., Ltd. was formally signed, well-known multinational pharmaceutical companies such as Bristol-Myers Squibb, Smith Kline, and Janssen have all set up production bases in China. In recent years, multinational pharmaceutical companies have set up R&D centers in China, which is a further recognition of China's pharmaceutical investment environment and innovation environment.
40 Years of Reform and Opening Up 15 Figures to Understand China's Pharmaceutical Industry (Figure 13)
4. Capitalization process
The development of the pharmaceutical industry is inseparable from the boost of capital. Since 1992, more than 300 pharmaceutical companies in China have been successfully listed, which has played a significant leading and exemplary role in the transformation and upgrading of China's pharmaceutical industry.
1. The number of listed pharmaceutical companies over the years
40 Years of Reform and Opening Up 15 Figures to Understand China's Pharmaceutical Industry (Figure 14)
2. Geographic distribution of listed pharmaceutical companies
Similar to the performance of the overall economy, Guangdong in the Pearl River Delta, Zhejiang, Jiangsu and Shanghai in the Yangtze River Delta, and Beijing in the Bohai Economic Circle are the regions with the most listed pharmaceutical companies.
The number of listed pharmaceutical companies in Tibet is as many as 5, ranking 20th. This is due to the fact that companies registered in Tibet enjoy many preferential conditions in terms of listing queues, etc., but most of their real production and office headquarters are not located in Tibet. , but mostly in inland cities such as Chengdu, Sichuan.
40 Years of Reform and Opening Up 15 Figures to Understand China's Pharmaceutical Industry (Figure 15)
Over the past 40 years of reform and opening up, China's pharmaceutical industry has made extraordinary achievements, and has continuously narrowed the gap with developed countries. With the continuous deepening of the new round of drug regulatory reform and the further implementation of a series of policies, the competitiveness of Chinese pharmaceutical companies will further increase. Improvement, especially R&D capability is playing an increasingly important role in global pharmaceutical R&D.
Integrating industry wisdom, paying equal attention to imitation and innovation, improving drug accessibility, and truly benefiting patients are important historical responsibilities that Chinese pharmaceutical companies should shoulder.
[This article was originally created by Dr. Zhang Ziran, welcome to reprint/forward, but please indicate the author, offenders will be held accountable! 】
This article was uploaded and authorized to be published by "Health Account" users. The above content (including text, pictures, and videos) does not represent the position of the health industry. "Health Account" is an information release platform that only provides information storage services. If you have any questions about reprinting or infringement, please contact the health community ( jkh@hmkx.cn ) to deal with it.
